Cutaneous Melanoma

P2, N=169, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed | Trial completion date: Jan 2026 --> Jan 2025

This approach, using hyaluronic acid nanoparticle (HANP)-formulated verteporfin (HANP/VP), concurrently induced nuclear- and mitochondrial-DNA damage, promoted immunogenic cell death (ICD), and drove T-lymphocyte infiltration into the tumor microenvironment (TME)...Overall, our findings established HANP/VP as a multifunctional nanomedicine that reprogrammed the TME and elicited potent antitumor immunity through dual DNA damage and STING activation. The study highlights a promising translational strategy for overcoming immunotherapeutic resistance in UM and converting immunologically "cold" tumors into "hot" ones, thereby improving responses to immune checkpoint blockade (ICB).

Integrative models combining TRAEs, ctDNA, miRNA signatures, and interferon-related gene expression offer a multi-dimensional framework for early, individualized response monitoring. Prospective validation, harmonization of assays, and incorporation into adaptive clinical workflows are key to translating these insights into personalized melanoma care.

P1, N=41, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2025 --> Jun 2026

We found that CNVs were the strongest discriminative features between PDMs and non-epidermal cutaneous metastases, with large-scale and focal CNVs abundant in metastases but not in PDMs. Notably, integrating BRAF copy number analysis with standard clinical criteria for diagnosing PDMs improved risk stratification after surgery. These data highlight the ability of panel-based genomic sequencing that enables detection of CNVs to inform clinical management of melanoma.

P=N/A, N=54, Completed, OHSU Knight Cancer Institute | N=17 --> 54

The study also identified six key genes, among which both the silencing and overexpression of GALNT2 significantly affect the proliferation and migration of melanoma cells. This study highlights the significance of MRGs in predicting patient survival and immunotherapy outcomes, providing insights for potential future targeted therapies.

This study found 8 genes that have been implicated in primary tumors or metastasis of other cancers which require further investigation into their involvement of metastasis in melanoma.

SE grade is useful to classify NACLMs in different groups distinguished by their clinical, pathological, and molecular features. These results endorse the new WHO classification of low- and high-CSD melanomas. Moreover, they highlight the importance of reporting the grade of SE in the pathological report.

The introduction of immunotherapy with checkpoint inhibitors significantly improved OS among patients with MBM and may have helped mitigate historical disparities in survival between men and women.

P=N/A, N=7500, Recruiting, Universitaire Ziekenhuizen KU Leuven

P1, N=10, Active, not recruiting, University Hospital, Basel, Switzerland | Trial completion date: Jun 2025 --> Jun 2026 | Recruiting --> Active, not recruiting